Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06279351
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2023-12-17
Brief Title:
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Sponsor:
Xinqiao Hospital of Chongqing
Organization:
Xinqiao Hospital of Chongqing
Study Overview
Official Title:
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1 To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer which has important clinical significance and provides a basis for subsequent large-scale research and clinical application
2 To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab FOLFIRI so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies
2 To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab FOLFIRI so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None